Synlogic announces positive top-line phase 2 data for phenylketonuria (pku); synb1934 advances to phase 3

Positive results include clinically meaningful phe reductions, with a 60% response rate and 42% reduction in plasma phe among responders across the study population

SYBX Ratings Summary

SYBX Quant Ranking